Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Omaveloxolone||RTA 408|RTA-408||Omaveloxolone (RTA 408) is an activator of Nrf2 (NFE2L2) and inhibitor of NF-kappa B, which inhibits tumor growth through regulation of antioxidant and pro-inflammatory gene expression (PMID: 25897966, PMID: 31487581).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Omaveloxolone||Phase I||Actionable||In a Phase I trial, treatment with Omaveloxolone (RTA 408) in patients with an advanced solid tumor led to a median progression-free survival of 1.5 months, an overall survival of 5.8 months, and one patient with lung cancer experienced stable disease for greater than 12 months (PMID: 28919776).||28919776|
|Unknown unknown||Advanced Solid Tumor||not applicable||Omaveloxolone||Preclinical - Cell culture||Actionable||In a preclinical study, Omaveloxolone (RTA 408) induced apoptosis and inhibited growth of several human tumor cell lines in culture (PMID: 25897966).||25897966|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02259231||Phase Ib/II||Ipilimumab Nivolumab Omaveloxolone||RTA 408 Capsules in Patients With Melanoma - REVEAL||Completed||USA||0|